Mafalda Raposo

Mafalda Raposo

Auto-generated profile, based on publicly available information

Mafalda Raposo

Instituto de Biologia Molecular e Celular (IBMC), Instituto de Investigação e Inovação em Saúde (i3S), Universidade do Porto

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2016 in Annals of Neurology
Verified
Journal Article
Open access
PDF file
CBConceição Bettencourt
Conceição Bettencourt
DHDavina Hensman‐Moss
Davina Hensman‐Moss
MFMichael Flower
Michael Flower
SWSarah Wiethoff
Sarah Wiethoff
ABAlexis Brice
Alexis Brice
LJLesley Jones
Lesley Jones
Objective: The polyglutamine diseases, including Huntington's disease (HD) and multiple spinocerebellar ataxias (SCAs), are among the commonest hereditary neurodegenerative diseases. They are caused by expanded CAG tracts, encoding glutamine, in different genes. Longer CAG repeat tracts are associated with earlier ages at onset, but this does not account for all of the difference, and the existence of additional genetic modifying factors has been suggested in these diseases. A recent genome‐wide association study (GWAS) in HD found association between age at onset and genetic variants in DNA repair pathways, and we therefore tested whether the modifying effects of variants in DNA repair genes have wider effects in the polyglutamine diseases.Methods: We assembled an independent cohort of 1,462 subjects with HD and polyglutamine SCAs, and genotyped single‐nucleotide polymorphisms (SNPs) selected from the most significant hits in the HD study.Results: In the analysis of DNA repair genes as a group, we found the most significant association with age at onset when grouping all polyglutamine diseases (HD+SCAs; p = 1.43 × 10–5). In individual SNP analysis, we found significant associations for rs3512 in FAN1 with HD+SCAs (p = 1.52 × 10–5) and all SCAs (p = 2.22 × 10–4) and rs1805323 in PMS2 with HD+SCAs (p = 3.14 × 10–5), all in the same direction as in the HD GWAS.Interpretation: We show that DNA repair genes significantly modify age at onset in HD and SCAs, suggesting a common pathogenic mechanism, which could operate through the observed somatic expansion of repeats that can be modulated by genetic manipulation of DNA repair in disease models. This offers novel therapeutic opportunities in multiple diseases. Ann Neurol 2016;79:983–990

20 July 2012 in Neurodegenerative Diseases
Verified
Journal Article
Closed access
PDF file
NKNadiya Kazachkova
Nadiya Kazachkova
MRMafalda Raposo
Mafalda Raposo
RMRafael Montiel
Rafael Montiel
TCTeresa Cymbron
Teresa Cymbron
CBConceição Bettencourt
Conceição Bettencourt
MLManuela Manuela de Medeiros Lima
Manuela Manuela de Medeiros Lima
Background: Machado-Joseph disease (MJD) is an autosomal dominant spinocerebellar ataxia caused by a CAG tract expansions in the ATXN3 gene. Patterns of mitochondrial damage associated with pathological findings of brain tissues could provide molecular biomarkers of this disorder. Objective: The potential of mitochondrial DNA (mtDNA) damage as a biomarker of MJD progression was investigated using a transgenic mouse model. Methods: DNA was obtained from affected (pontine nuclei) and nonaffected tissues (hippocampus and blood) of transgenic animals of three distinct age groups: 8 weeks, before onset of the phenotype; 16 weeks, at onset, and 24 weeks, at well-established phenotype. Wild-type littermate mice, serving as controls, were analyzed for the same tissues and age groups. mtDNA damage was studied by fluorescence-based quantitative PCR in 84 transgenic and 93 wild-type samples. Results: A clear pattern of decrease in mtDNA copy number with age and accumulation of 3,867-bp deletions at the initial stages (both being more pronounced in transgenic mice) was observed. Pontine nuclei, the affected tissue in transgenic mice, displayed 1.5 times less copies of mtDNA than nonaffected brain tissue hippocampus (odds ratio = 1.21). Pontine nuclei displayed the highest percentage of mtDNA deletions (6.05% more in transgenic mice). Conclusion: These results suggest that mtDNA damage is related to the initiation of the phenotype in transgenic mice; mtDNA 3,867-bp deletions may be a biomarker of the initial stages of the disease.

26 May 2022 in European Journal of Neurology
Verified
Journal Article
Open access
HGHector Garcia-Moreno
Hector Garcia-Moreno
MPMercedes Prudencio
Mercedes Prudencio
GTGilbert Thomas‐Black
Gilbert Thomas‐Black
NSNita Solanky
Nita Solanky
KJKaren Jansen-West
Karen Jansen-West
PGPaola Giunti
Paola Giunti
Background and purpose: Clinical trials in spinocerebellar ataxia type 3 (SCA3) will require biomarkers for use as outcome measures.Methods: To evaluate total tau (t‐tau), glial fibrillary acidic protein (GFAP), ubiquitin carboxy‐terminal hydrolase L1 (UCHL1) and neurofilament light‐chain (NfL) as fluid biomarkers in SCA3, ATXN3 mutation carriers (n = 143) and controls (n = 172) were clinically assessed, and the plasma concentrations of the four proteins were analysed on the Simoa HD‐1 platform. Eleven ATXN3 mutation carrier cerebrospinal fluid samples were analysed for t‐tau and phosphorylated tau (p‐tau181). A transgenic SCA3 mouse model (MJDTg) was used to measure cerebellar t‐tau levels.Results: Plasma t‐tau levels were higher in mutation carriers below the age of 50 compared to controls, and the Inventory of Non‐Ataxia Signs was associated with t‐tau in ataxic patients (p = 0.004). Pre‐ataxic carriers showed higher cerebrospinal fluid t‐tau and p‐tau181 concentrations compared to ataxic patients (p = 0.025 and p = 0.014, respectively). Cerebellar t‐tau was elevated in MJDTg mice compared to wild‐type (p = 0.033) only in the early stages of the disease. GFAP and UCHL1 did not show higher levels in mutation carriers compared to controls. Plasma NfL concentrations were higher in mutation carriers compared to controls, and differences were greater for younger carriers. The Scale for the Assessment and Rating of Ataxia was the strongest predictor of NfL in ataxic patients (p < 0.001).Conclusion: Our results suggest that tau might be a marker of early disease stages in SCA3. NfL can discriminate mutation carriers from controls and is associated with different clinical variables. Longitudinal studies are required to confirm their potential role as biomarkers in clinical trials.

1 December 2011 in Archives of Neurology
Verified
Journal Article
Closed access
PDF file
CBConceição Bettencourt
Conceição Bettencourt
MRMafalda Raposo
Mafalda Raposo
NKNadiya Kazachkova
Nadiya Kazachkova
TCTeresa Cymbron
Teresa Cymbron
CSCristina Santos
Cristina Santos
MLManuela Manuela de Medeiros Lima
Manuela Manuela de Medeiros Lima
Research from JAMA Neurology — The APOE ε2 Allele Increases the Risk of Earlier Age at Onset in Machado-Joseph Disease

16 August 2021 in Movement Disorders
Verified
Journal Article
Open access
PDF file
JHJeannette Hübener-Schmid
Jeannette Hübener-Schmid
KKKirsten Kuhlbrodt
Kirsten Kuhlbrodt
JMJulien Peladan Msc
Julien Peladan Msc
JFJennifer Faber
Jennifer Faber
MSMagda M. Santana
Magda M. Santana
OROlaf Riess
Olaf Riess
Background: Spinocerebellar ataxia type 3 is a rare neurodegenerative disease caused by a CAG repeat expansion in the ataxin‐3 gene. Although no curative therapy is yet available, preclinical gene‐silencing approaches to reduce polyglutamine (polyQ) toxicity demonstrate promising results. In view of upcoming clinical trials, quantitative and easily accessible molecular markers are of critical importance as pharmacodynamic and particularly as target engagement markers.Objective: We aimed at developing an ultrasensitive immunoassay to measure specifically polyQ‐expanded ataxin‐3 in plasma and cerebrospinal fluid (CSF).Methods: Using the novel single molecule counting ataxin‐3 immunoassay, we analyzed cross‐sectional and longitudinal patient biomaterials.Results: Statistical analyses revealed a correlation with clinical parameters and a stability of polyQ‐expanded ataxin‐3 during conversion from the pre‐ataxic to the ataxic phases.Conclusions: The novel immunoassay is able to quantify polyQ‐expanded ataxin‐3 in plasma and CSF, whereas ataxin‐3 levels in plasma correlate with disease severity. Longitudinal analyses demonstrated a high stability of polyQ‐expanded ataxin‐3 over a short period. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society

24 October 2011 in BMC Neurology
Verified
Journal Article
Open access
PDF file
CBConceição Bettencourt
Conceição Bettencourt
CSCristina Santos
Cristina Santos
PCPaula Coutinho
Paula Coutinho
PRPatrizia Rizzu
Patrizia Rizzu
JVJoão Vasconcelos
João Vasconcelos
MLManuela Manuela de Medeiros Lima
Manuela Manuela de Medeiros Lima
Machado-Joseph disease (MJD), or spinocerebellar ataxia type 3 (SCA3), is an autosomal dominant neurodegenerative disorder of late onset, which is caused by a CAG repeat expansion in the coding region of the ATXN3 gene. This disease presents clinical heterogeneity, which cannot be completely explained by the size of the repeat tract. MJD presents extrapyramidal motor signs, namely Parkinsonism, more frequently than the other subtypes of autosomal dominant cerebellar ataxias. Although Parkinsonism seems to segregate within MJD families, only a few MJD patients develop parkinsonian features and, therefore, the clinical and genetic aspects of these rare presentations remain poorly investigated. The main goal of this work was to describe two MJD patients displaying the parkinsonian triad (tremor, bradykinesia and rigidity), namely on what concerns genetic variation in Parkinson's disease (PD) associated loci (PARK2, LRRK2, PINK1, DJ-1, SNCA, MAPT, APOE, and mtDNA tRNA Gln T4336C).